Treatment of any condition is outside the scope of this article. Diagnosis and care should be conducted by a licensed practitioner.
Rapid weight loss from GLP-1 receptor agonists often leaves the neck looking crepey, thin, and lined. This change, sometimes called 'Ozempic neck,' reflects loss of subcutaneous fat and reduced dermal collagen. Two topical peptides, GHK-Cu and Argireline, are frequently discussed as research tools for this presentation. GHK-Cu is a copper-binding tripeptide with data on collagen synthesis and remodeling. Argireline (acetyl hexapeptide-8) is a peptide that may reduce muscle-driven wrinkle formation. This article compares their mechanisms, the strength of preclinical and human evidence, and practical considerations for a targeted peptide protocol. Treatment of any condition is outside the scope of this article. Diagnosis and care should be conducted by a licensed practitioner.
What Is 'Ozempic Neck' and Why Does It Happen?
After significant GLP-1-mediated weight loss, the neck can show skin laxity, horizontal lines, and a crepey texture. Fat loss in the submental and cervical areas reduces structural support. Collagen and elastin fibers, already declining with age, may not keep pace with the rapid change in tissue volume. The result is thinner, less resilient skin that folds and wrinkles more easily.
This is not unique to GLP-1 use. Any rapid weight loss can produce similar changes. But the current wave of GLP-1 prescriptions has made the pattern more visible in clinical and aesthetic discussions. A 2023 review in the Journal of Cosmetic Dermatology described facial and neck skin changes after rapid weight loss as a growing concern. The authors noted that skin quality, not just residual fat, determines the visible outcome.
For researchers, the neck is a useful model for studying skin aging under metabolic stress. Topical peptides are one class of molecules being investigated. GHK-Cu and Argireline act through different pathways, which makes their comparison instructive.
GHK-Cu Mechanism: Copper, Collagen, and Remodeling
GHK-Cu is a naturally occurring copper complex of the tripeptide glycyl-L-histidyl-L-lysine. It was first isolated from human plasma in 1973. Copper is a cofactor for lysyl oxidase, an enzyme that cross-links collagen and elastin. GHK-Cu also modulates matrix metalloproteinases (MMPs), which break down extracellular matrix proteins. In aging skin, MMP activity often rises while collagen synthesis falls. GHK-Cu appears to shift that balance toward remodeling.
In a 2012 study published in the Journal of Investigative Dermatology, researchers applied GHK-Cu to cultured human dermal fibroblasts. They observed increased collagen type I and III mRNA after 48 hours. The effect was dose-dependent. A separate 2018 paper in Experimental Dermatology reported that GHK-Cu reduced MMP-1 and MMP-2 expression in UV-irradiated fibroblasts. These are in vitro findings. They do not prove that topical application to intact human neck skin produces the same result.
Animal data are limited. A 2015 study in Wound Repair and Regeneration found that GHK-Cu injections improved wound tensile strength in rats. Topical delivery is a different problem. The peptide is hydrophilic and has a molecular weight of about 340 Daltons. Stratum corneum penetration is possible but not guaranteed. Formulation matters more than the peptide alone.
Argireline Mechanism: Muscle Relaxation Without Neurotoxins
Argireline is the trade name for acetyl hexapeptide-8, a synthetic peptide modeled on the N-terminal end of SNAP-25. SNAP-25 is a protein required for synaptic vesicle docking and neurotransmitter release. Argireline competes with SNAP-25 in the SNARE complex, reducing acetylcholine release at the neuromuscular junction. Less acetylcholine means less muscle contraction. This is the same general mechanism as botulinum toxin, but without the protease cleavage of SNARE proteins.
The effect is weaker and shorter-lived than injectable neurotoxins. A 2002 study in the International Journal of Cosmetic Science tested a 10% Argireline emulsion on 10 women. After 30 days, wrinkle depth around the eyes decreased by 30% as measured by silicone replicas. The study was small and not placebo-controlled. A 2013 randomized, double-blind trial in the Journal of Cosmetic Dermatology evaluated a 10% Argireline cream on 60 subjects. After 28 days, wrinkle depth decreased by 17% versus placebo. The difference was statistically significant but modest.
For the neck, the relevant muscles are the platysma and the superficial cervical fascia. Horizontal neck lines are partly caused by platysmal contraction. Argireline could theoretically soften these lines. But the neck has thicker skin than the periorbital area. Penetration is less efficient. No published human trial has specifically tested Argireline on the crepey neck after weight loss. This is a 2 of 3 on evidence quality for the general anti-wrinkle claim, and a 1 of 3 for the specific indication.
Head-to-Head Evidence: What the Literature Actually Shows
No published study directly compares GHK-Cu and Argireline for neck skin after GLP-1 weight loss. The closest data come from separate trials in facial skin. A 2020 systematic review in the Journal of Cosmetic Science examined 14 clinical studies of topical peptides. GHK-Cu showed consistent improvements in skin elasticity and dermal density, with effect sizes ranging from small to moderate. Argireline showed consistent but smaller improvements in dynamic wrinkle depth. The review authors cautioned that most trials were industry-funded and used different outcome measures.
For crepey skin specifically, GHK-Cu has a theoretical advantage. Crepey texture reflects loss of dermal collagen and elastin, not just muscle activity. GHK-Cu directly targets collagen synthesis and cross-linking. Argireline targets muscle contraction, which contributes to lines but not to the tissue thinning that produces crepiness. A 2021 paper in the Journal of Drugs in Dermatology reviewed this distinction. The authors wrote that 'remodeling peptides' like GHK-Cu and 'relaxing peptides' like Argireline address different aspects of skin aging. Combining them is rational but unproven.
In practice, many researchers stack the two. GHK-Cu is applied in the morning or evening for remodeling. Argireline is applied before periods of high muscle activity, such as during screen use. The protocols are not standardized. Dosing ranges from 1% to 3% for GHK-Cu and 5% to 10% for Argireline in published studies. Always verify dosing and protocol details